Beer Trevor W
Cutaneous Pathology, Nedlands, Western Australia 6012, Australia.
J Cutan Pathol. 2012 Jan;39(1):29-32. doi: 10.1111/j.1600-0560.2011.01800.x.
The histopathological features of atypical fibroxanthoma (AFX) overlap with those of poorly differentiated carcinoma, melanoma and leiomyosarcoma in the skin. As there are no specific stains to identify AFX, the diagnosis is essentially one of exclusion and requires completion of a panel of immunostains. Recently, it has been suggested that the macrophage/monocyte-specific marker CD163 is of value in identifying AFX. To investigate this claim, 57 AFX were stained for CD163. Only 21 of 57 (37%) of AFX stained positively, and intratumoral macrophages confounded interpretation of the stain at times. In four cases, it was not possible to definitively interpret the tumor staining reaction because of this effect. While a lack of stainable CD163 antigenicity may indicate that AFX is not of histiocytic lineage, it is conceivable that expression of the antigen has been lost for some reason in cells that are in fact of macrophage lineage. In summary, CD163 only stains a minority of AFX and staining results can be difficult to interpret. CD163 is therefore of very limited value in the diagnosis of AFX. Beer TW. CD163 is not a sensitive marker for identification of atypical fibroxanthoma.
非典型纤维黄色瘤（AFX）的组织病理学特征与皮肤中低分化癌、黑色素瘤和平滑肌肉瘤的特征重叠。由于没有特异性染色来识别AFX，诊断基本上是排除性诊断，需要完成一组免疫染色。最近，有人提出巨噬细胞/单核细胞特异性标志物CD163在识别AFX方面具有价值。为了研究这一说法，对57例AFX进行了CD163染色。57例AFX中只有21例（37%）呈阳性染色，肿瘤内巨噬细胞有时会干扰染色结果的解读。在4例病例中，由于这种影响，无法明确解读肿瘤染色反应。虽然缺乏可染色的CD163抗原性可能表明AFX不是组织细胞谱系，但可以想象，实际上属于巨噬细胞谱系的细胞中，该抗原的表达由于某种原因已经丧失。总之，CD163仅对少数AFX染色，且染色结果可能难以解读。因此，CD163在AFX诊断中的价值非常有限。比尔·T·W。CD163不是识别非典型纤维黄色瘤的敏感标志物。
